Nobuhiro Nakazawa1, Kyoichi Ogata1, Takehiko Yokobori2, Munenori Ide3, Seded Baatar4, Yasunari Ubukata4, Akiharu Kimura4, Norimichi Kogure4, Makoto Sohda4, Hiroyuki Kuwano4, Hiroshi Saeki4, Ken Shirabe4. 1. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan kogata@gunma-u.ac.jp bori45@gunma-u.ac.jp nakazawa75@yahoo.co.jp. 2. Department of Innovative Cancer Immunotherapy, Gunma University Graduate School of Medicine, Maebashi, Japan kogata@gunma-u.ac.jp bori45@gunma-u.ac.jp nakazawa75@yahoo.co.jp. 3. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan. 4. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Abstract
BACKGROUND/AIM: We investigated whether the expression of inositol 1, 4, 5-trisphosphate receptor-binding protein released with inositol 1, 4, 5-trisphosphate (IRBIT) in clinical gastric cancer (GC) patients could predict the therapeutic response to postoperative adjuvant chemotherapy. MATERIALS AND METHODS: Immunohistochemistry was used to investigate IRBIT expression in 115 GC patients. To clarify whether IRBIT had a relationship with the therapeutic effects of chemotherapy, we compared two groups - 62 patients treated with postoperative adjuvant chemotherapy and 53 patients treated with postoperative adjuvant chemotherapy. RESULTS: Regarding the postoperative adjuvant chemotherapy-free group, we did not find any statistically significant correlation between clinicopathological features and recurrence regardless of the expression of IRBIT. In contrast, in the group receiving postoperative adjuvant chemotherapy, a significant association was found between IRBIT expression and both overall and disease-free survival. CONCLUSION: IRBIT may be used as a useful predictive marker for chemotherapy. Copyright
BACKGROUND/AIM: We investigated whether the expression of inositol 1, 4, 5-trisphosphate receptor-binding protein released with inositol 1, 4, 5-trisphosphate (IRBIT) in clinical gastric cancer (GC) patients could predict the therapeutic response to postoperative adjuvant chemotherapy. MATERIALS AND METHODS: Immunohistochemistry was used to investigate IRBIT expression in 115 GC patients. To clarify whether IRBIT had a relationship with the therapeutic effects of chemotherapy, we compared two groups - 62 patients treated with postoperative adjuvant chemotherapy and 53 patients treated with postoperative adjuvant chemotherapy. RESULTS: Regarding the postoperative adjuvant chemotherapy-free group, we did not find any statistically significant correlation between clinicopathological features and recurrence regardless of the expression of IRBIT. In contrast, in the group receiving postoperative adjuvant chemotherapy, a significant association was found between IRBIT expression and both overall and disease-free survival. CONCLUSION:IRBIT may be used as a useful predictive marker for chemotherapy. Copyright